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Abstract
Introduction Our previous study has reported that, in patients
with untreated new-onset lupus (UNOL), there was an abnormal
increase in the number of CD4+CD25-Foxp3+  T cells that
correlated with disease activity and significantly decreased after
treatment. However, little is known about the nature of this cell
entity. The aim of this study was to explore the nature of
abnormally increased CD4+CD25-Foxp3+  T cells in UNOL
patients.
Methods The expressions of surface (CD4, CD25, CD127,
chemokine receptor 4 [CCR4], glucocorticoid-induced tumor
necrosis factor receptor [GITR], and cytotoxic T lymphocyte-
associated antigen 4 [CTLA-4]) and intracellular (Foxp3)
molecules as well as cytokine synthesis of peripheral blood
mononuclear cells from 22 UNOL patients were analyzed by
flow cytometry. The proliferative and suppressive capacities of
different T-cell subgroups from UNOL patients were also
assessed.
Results In UNOL patients, the percentages of CD127low/- in
CD25high, CD25low, and CD25- subpopulations of CD4+Foxp3+
T cells were 93.79% ± 3.48%, 93.66% ± 2.31%, and 91.98%
± 2.14%, respectively (P > 0.05), whereas the expressions of
Foxp3 showed significant differences in CD25high (91.38% ±
2.57%), CD25low (71.89% ± 3.31%), and CD25- (9.02% ±
2.21%) subpopulations of CD4+CD127low/- T cells (P < 0.01).
The expressions of surface CCR4, GITR, and CTLA-4 on
CD4+CD25-Foxp3+  T cells were significantly less than
CD4+CD25+Foxp3+  T cells (P  < 0.05). Moreover, unlike
CD4+CD25+Foxp3+ T cells, CD4+CD25-Foxp3+ T cells also
synthesized interferon-gamma, interleukin (IL)-4, IL-2, and IL-17
(P < 0.05), though less than CD4+CD25+Foxp3- T cells. The
suppressive capacity was most prominent in
CD4+CD25highCD127low/-, followed by
CD4+CD25lowCD127low/-. CD4+CD25-CD127- T cells showed
the least suppressive capacity, which was similar to the effector
T cells.
Conclusions CD4+CD25-Foxp3+ T cells in UNOL patients are
different from regulatory T cells, both phenotypically and
functionally. CD127 is not an appropriate surface marker for
intracellular Foxp3 in CD4+CD25- T cells.
CCR4: chemokine receptor 4; CTLA-4: cytotoxic T lymphocyte-associated antigen 4; FACS: fluorescence-activated cell sorting; FITC: fluorescein 
isothiocyanate; GITR: glucocorticoid-induced tumor necrosis factor receptor; IFN-γ: interferon-gamma; IL: interleukin; nTreg: naturally occurring reg-
ulatory T cell; PBMC: peripheral blood mononuclear cell; PE: phycoerythrin; SLE: systemic lupus erythematosus; Teff: effector T cell; Treg: regulatory 
T cell; TSLP: thymic stromal lymphopoietin; UNOL: untreated new-onset lupus.Arthritis Research & Therapy    Vol 11 No 5    Yang et al.
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Introduction
Systemic lupus erythematosus (SLE) is a systemic autoim-
mune disease characterized by polyclonal activation of B and
T lymphocytes. It remains controversial whether the frequency
and function of CD4+CD25+Foxp3+ regulatory T cells (Tregs)
are altered in SLE patients [1]. In our previous study, we found
that, in patients with untreated new-onset lupus (UNOL), there
was an abnormal increase in the number of CD4+CD25-
Foxp3+ T cells (instead of CD4+CD25+Foxp3+ Tregs) that cor-
related with disease activity and significantly decreased after
glucocorticoid treatment [2]. As Foxp3 is currently thought to
be one of the best markers for naturally occurring Tregs
(nTregs), it is intriguing to explore the nature of this abnormally
increased cell entity in UNOL patients.
To answer this question requires direct functional assay and
indirect phenotypic analysis. The crucial step of function assay
is to find a proper surface substitute for intracellular Foxp3 in
CD4+CD25- T cells. A study has suggested that low expres-
sion of CD127 (receptor alpha chain of interleukin-7 [IL-7])
could be used as a surface marker for intracellular Foxp3 in
human CD4+CD25+ Tregs [3]. Whether this is still true in
CD4+CD25- T cells remains to be defined.
Other cell surface molecules, including glucocorticoid-
induced tumor necrosis factor receptor (GITR), cytotoxic T
lymphocyte-associated antigen 4 (CTLA-4), and chemokine
receptor 4 (CCR4), have been investigated in Tregs. GITR has
been found to be increased on CD4+CD25+ Tregs and plays
a key role in dominant immunological self-tolerance [4,5].
CTLA-4 is also predominantly expressed on CD4+CD25+
Tregs from thymus and peripheral blood and participates in the
maintenance of immunologic self-tolerance [6]. Another cell
surface molecule, CCR4, is selectively expressed on Th2-type
cells and Tregs [7-9]. Foxp3-transduced naïve CD4+CD25- T
cells have increased expression of CCR4 and obtain suppres-
sive function as CD4+CD25+ Tregs [10].
Following our report, a recent study declared that these
CD4+CD25-Foxp3+ T cells functionally resembled conven-
tional Tregs by fluorescence-activated cell sorting (FACS)
CD4+CD25-CD127- T cells as a substitute for CD4+CD25-
Foxp3+ T cells from SLE patients [11]. In our current study,
however, by analyzing the correlation of CD127 and Foxp3 on
CD4+CD25-, CD4+CD25low, and CD4+CD25high T cells, we
found that, unlike in CD4+CD25high T cells, CD127low/- was not
a perfect surface marker for intracellular Foxp3 in CD4+CD25-
T cells; therefore, CD4+CD25-CD127low/- T cells could not be
used as a live substitute for CD4+CD25-Foxp3+ T cells to per-
form functional assay. We then set out to examine surface
expressions of GITR, CTLA-4, and CCR4 and (importantly)
cytokine synthesis function of CD4+CD25-Foxp3+,
CD4+CD25+Foxp3+, and CD4+CD25+Foxp3-  T cells. We
found that CD4+CD25-Foxp3+ T cells in UNOL patients are
different from Tregs, both phenotypically and functionally.
Materials and methods
Patients and healthy controls
Twenty-two UNOL patients of Chinese ethnicity (19 women
and 3 men) were recruited in this study. All patients fulfilled the
SLE classification criteria of the American College of Rheuma-
tology. The mean age was 27.8 ± 9.1 years, and disease dura-
tion was 42 ± 28 days. Systemic lupus erythematosus disease
activity index (SLEDAI) was 9.3 ± 5.2. Twenty-five gender- and
age-matched healthy volunteers were involved as healthy con-
trols. This study was approved by the ethics committee of
Peking Union Medical College Hospital, and informed consent
was obtained from each patient and healthy volunteer.
Antibodies
Except as otherwise indicated, the monoclonal antibodies and
reagents were obtained from eBioscience, Inc. (San Diego,
CA, USA): fluorescein isothiocyanate (FITC)-conjugated anti-
human CD4 (L3T4), PEcy5-conjugated anti-human CD25 (IL-
2R), phycoerythrin (PE)-conjugated anti-human GITR, PE-con-
jugated anti-human CTLA-4, allophycocyanin-conjugated anti-
human Foxp3, and PE-conjugated anti-human IL-17 and their
respective isotype controls. PEcy7-conjugated CCR4, PE-
conjugated anti-human interferon-gamma (IFN-γ), PE-conju-
gated anti-human IL-2, and PE-conjugated anti-human IL-4
and their matched isotype controls were purchased from BD
Pharmingen (San Diego, CA, USA).
Preparation of peripheral blood mononuclear cells and 
cell culture
Peripheral blood was collected, and peripheral blood mononu-
clear cells (PBMCs) were prepared by Ficoll-Hypaque density
gradient centrifugation. For intracellular cytokine staining,
freshly isolated PBMCs were cultured in complete RPMI 1640
media (Invitrogen Ltd., Paisley, UK) supplemented with 10%
fetal bovine serum (HyClone, Logan, UT, USA), 100 U/mL
penicillin, and 100 μg/L streptomycin, as well as 20 ng/mL
phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich, St.
Louis, MO, USA) and 500 ng/mL ionomycin (Sigma-Aldrich),
in the presence of 10 μg/mL Brefeldin A (BD Pharmingen) in
a humidified CO2-containing atmosphere at 37°C for 6 hours.
Flow cytometry analysis
PBMCs were washed in phosphate-buffered saline containing
2% fetal calf serum and 0.09% NaN3. Cells (1 × 106) were
incubated with FITC-CD4 (20 μL) and PEcy5-CD25 (20 μL)
and with PEcy7-CCR4 (5 μL), PE-GITR (20 μL), or PE-CTLA4
(20 μL) at 4°C for 30 minutes. Subsequently, cells were per-
forated, and intracellular staining for Foxp3 and for PE-anti-
IFN-γ (20 μL), PE-anti-IL-4 (20 μL), PE-anti-IL-2 (20 μL), or PE-
anti-IL-17 (20 μL) was performed according to the instructions
of the manufacturer. Stained cells were then analyzed by a
FACScanto (BD Biosciences, San Jose, CA, USA).Available online http://arthritis-research.com/content/11/5/R153
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Functional assays
For the assessment of T-cell proliferation, FACS-sorted
CD4+CD25-CD127+, CD4+CD25highCD127low/-,
CD4+CD25lowCD127low/-, and CD4+CD25-CD127-  from
PBMCs of UNOL patients were stimulated by soluble anti-
CD3 monoclonal antibody (200 ng/mL) in U-bottom 96-well
plates. For the assessment of suppressive function of different
T-cell subpopulations, 5 × 104  CD4+CD25highCD127low/-,
CD4+CD25lowCD127low/-, or CD4+CD25-CD127-  T cells
were respectively cultured in the presence of CD4+CD25-
CD127+ T cells (cell ratio 1:1) and irradiated PBMCs (1 ×
105) in RPMI 1640 plus 10% fetal calf serum at 37°C in a
humidified CO2-containing atmosphere for 72 hours. CCK-8
solution was added, and optical density value was measured
4 hours later.
Statistical analysis
All statistical analyses were performed using SPSS 13.0 soft-
ware (SPSS Inc., Chicago, IL, USA). Numbers of CD4+ sub-
populations were compared using the Student t test. A P value
of less than 0.05 was considered significant.
Results
Correlations of CD127 and Foxp3 expressions on 
CD4+CD25-, CD4+CD25low, and CD4+CD25high T cells from 
UNOL patients
CD4+ T cells were divided into three subgroups by CD25
expression: CD4+CD25high, CD4+CD25low, and CD4+CD25-
T cells. We gated CD127low/- expression on Foxp3+ T cells
and backgated Foxp3 expression on CD127low/-  T cells,
respectively. We found that all CD4+Foxp3+ T cells had a low
expression level of CD127, regardless of CD25 expression.
Percentages of CD127low/- in CD25high, CD25low, and CD25-
subpopulations of CD4+Foxp3+  T cells were 93.79% ±
3.48%, 93.66% ± 2.31%, and 91.98% ± 2.14%, respectively
(P > 0.05) (Figure 1). On the other hand, the expressions of
Foxp3 on CD4+CD127low/- T cells showed significant differ-
ences in CD25high (91.38% ± 2.57%), CD25low (71.89% ±
3.31%), and CD25- (9.02% ± 2.21%) subpopulations (P <
0.01) (Figure 2). Foxp3 expressions in CD4+CD127low/- T cells
were high in CD25high but low in CD25- subpopulations. This
result suggested that, unlike in CD4+CD25high  T cells,
CD127low/- was not a perfect candidate surface marker for
Figure 1
Expressions of CD127 on CD25high, CD25low, and CD25- subpopulations of CD4+ Foxp3+ T cells from patients with untreated new-onset lupus  (UNOL) Expressions of CD127 on CD25high, CD25low, and CD25- subpopulations of CD4+ Foxp3+ T cells from patients with untreated new-onset lupus 
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intracellular Foxp3 in CD4+CD25-  T cells and that
CD4+CD25-CD127low/- T cells could not be used as a live
substitute for CD4+CD25-Foxp3+ T cells to perform functional
assay.
Expressions of GITR, CTLA-4, CCR4 and effector T cell-
related cytokines on CD4+ subpopulations from UNOL
patients
Expressions of GITR, CTLA-4, CCR4, and effector T cell-
related cytokines (IFN-γ, IL-4, IL-2, and IL-17) on 
CD4+CD25-Foxp3+, CD4+CD25+Foxp3-, 
CD4+CD25+Foxp3+, and CD4+CD25-Foxp3- T cells from 
UNOL patients and healthy controls
As shown in Table 1 and Figure 3, in UNOL patients, there was
no significant difference between CD4+CD25-Foxp3+  and
CD4+CD25+Foxp3- T cells in the expressions of GITR, CTLA-
4, and CCR4 (P > 0.05), whereas they were both less than
CD4+CD25+Foxp3+ T cells (P < 0.01). Moreover, the expres-
sions of effector T cell (Teff)-related cytokines, including IFN-
γ, IL-4, IL-2, and IL-17, were analyzed to examine cytokine syn-
thesis capacity of CD4+CD25-Foxp3+ T cells. As shown in
Table 2 and Figure 4, in UNOL patients, unlike Tregs
(CD4+CD25+Foxp3+), CD4+CD25-Foxp3+ T cells also syn-
thesized IFN-γ, IL-4, IL-2, and IL-17 (P < 0.05), though less
than Teffs (CD4+CD25+Foxp3-).
Functional assays of T-cell subgroups from UNOL 
patients
CD4+CD25-CD127+  (Teffs), CD4+CD25highCD127low/-
(Tregs), CD4+CD25lowCD127low/-, and CD4+CD25-CD127- T
cells from UNOL patients were sorted respectively. First, all
Figure 2
Expressions of Foxp3 in CD25high, CD25low, and CD25- subpopulations of CD4+ CD127low/- T cells from patients with untreated new-onset lupus  (UNOL) Expressions of Foxp3 in CD25high, CD25low, and CD25- subpopulations of CD4+ CD127low/- T cells from patients with untreated new-onset lupus 
(UNOL).
Table 1
Expressions of GITR, CTLA-4, and CCR4 on CD4+ subpopulations from untreated new-onset lupus patients and healthy controls
Subgroups GITR, % CTLA-4, % CCR4, %
UNOL HC UNOL HC UNOL HC
CD4+ CD25- Foxp3+ 4.41 ± 0.67 5.13 ± 1.23 39.78 ± 1.67 53.12 ± 4.29 35.76 ± 2.53 34.33 ± 2.90
CD4+ CD25+ Foxp3+ 22.49 ± 1.75 29.88 ± 3.24 73.89 ± 2.76 81.66 ± 4.85 49.44 ± 2.75 56.91 ± 3.17
CD4+ CD25+ Foxp3- 6.52 ± 0.89 4.89 ± 1.32 33.57 ± 2.98 40.59 ± 5.55 31.99 ± 3.76 32.23 ± 5.54
CD4+ CD25- Foxp3- 5.35 ± 0.88 11.77 ± 2.75 15.05 ± 2.24 16.06 ± 4.25 13.58 ± 2.57 10.11 ± 3.63
Values are presented as mean ± standard deviation. CCR4, chemokine receptor 4; CTLA-4: Cytotoxic T lymphocyte-associated antigen 4; GITR: 
glucocorticoid-induced tumor necrosis factor receptor; HC: healthy controls; UNOL: patients with untreated new-onset lupus.Available online http://arthritis-research.com/content/11/5/R153
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four subgroups were stimulated with anti-CD3 and assessed
for their proliferative ability. CD4+CD25highCD127low/- Tregs
(0.205 ± 0.043) were found to be anergic compared with
CD4+CD25-CD127+  Teffs (0.421 ± 0.102). Similarly,
CD4+CD25lowCD127low/- (0.210 ± 0.062) and CD4+CD25-
CD127- (0.272 ± 0.081) T cells showed a reduced prolifera-
tive response (Figure 5).
Then, CD4+CD25highCD127low/-, CD4+CD25lowCD127low/-,
and CD4+CD25-CD127- T cells were respectively cocultured
with CD4+CD25-CD127+ Teffs. The suppressive capacity as
shown by optical density was most prominent in
CD4+CD25highCD127low/-  (0.213 ± 0.032), followed by
CD4+CD25lowCD127low/- (0.281 ± 0.061) and CD4+CD25-
CD127- (0.387 ± 0.087). CD4+CD25-CD127- T cells showed
the least suppressive capacity, which was similar to the Teffs,
in line with its lesser expression of Foxp3 (9.02% ± 2.21%)
(Figure 5).
Discussion
Foxp3 is currently thought to be one of the best markers for
nTregs. It plays a pivotal role in the development and matura-
tion of Tregs. Foxp3-deficient mice develop systemic autoim-
mune disease, and evidence from adoptive transfer
experiments suggests that this is the direct result of nTreg
defect. Moreover, overexpression of Foxp3 in murine CD4+ T
cells is sufficient to generate Tregs in vitro. In humans, Foxp3
deficiency also leads to a systemic autoimmune disease
known as IPEX (immune dysregulation, polyendocrinopathy,
enteropathy X-linked syndrome). It has been shown, however,
that the expression of Foxp3 is necessary, but not sufficient, to
confer regulatory function of Tregs. Foxp3 is also expressed
on some activated CD4+ T cells [12]. Bonelli and colleagues
[13] reported that Foxp3 expression on CD4+ T cells signifi-
cantly correlated with CD69 expression and that Foxp3 might
be associated with T-cell activation.
In our previous study, we found that a significant increase of
CD4+CD25-Foxp3+ T cells in UNOL patients correlated with
disease activity and that the cell number significantly
decreased after glucocorticoid treatment [2]. Whether these
cells are Tregs or activated Teffs remains to be determined.
Functional assay would be a direct way to identify the nature
of CD4+CD25-Foxp3+ T cells if only we could find a proper
surface substitute for intracellular Foxp3 in CD4+CD25- T
cells. A study showed that low expression of CD127 could be
used as a surface marker for intracellular Foxp3 in human
CD4+CD25+ Tregs [3]. CD127 is expressed not only on lym-
phocytes, but also on monocytes and dendritic cells. Its ligand,
IL-7, is a pivotal cytokine involved in the development and sur-
vival of T and B lymphocytes [14]. In addition, thymic stromal
lymphopoietin (TSLP) signals through CD127 in a het-
erodimeric complex with TSLP receptor [15]. TSLP-activated
dendritic cells might participate in the homeostatic mainte-
nance of CD4+ and development of Tregs in thymus [16].
In this study, we gated and backgated expressions of CD127
and Foxp3 in CD4+CD25-  T cells. We confirmed that
CD4+CD25highCD127low/- could be used as a substitute for
isolating CD4+CD25highFoxp3+ Tregs, whereas the expres-
sion of Foxp3 on CD4+CD127low/- T cells showed significant
differences in CD25high (91.38% ± 2.57%), CD25low (71.89%
± 3.31%), and CD25- (9.02% ± 2.21%) subpopulations.
Foxp3 expression on CD4+CD127low/- T cells was high in both
CD25high and CD25low subpopulations but low in CD25- sub-
populations. This result suggested that, unlike in
CD4+CD25high T cells, CD127 was not a perfect surface
marker for intracellular Foxp3 in CD4+CD25- T cells. It is also
important to note that, although the CD25low population lies
adjacent to CD25- on a FACS plot (as shown in Figure 2), they
belong to two different cell entities as their Foxp3 expressions
as well as their suppressive capacity and response to in vitro
stimulation were different. If the sorted CD25- subgroup was
Table 2
Expressions of IFN-γ, IL-4, IL-2, and IL-17 on CD4+ subpopulations from untreated new-onset lupus patients and healthy controls
IFN-γ, % IL-4, % IL-2, % IL-17, %
UNOL HC UNOL HC UNOL HC UNOL HC
CD4+ CD25- 
Foxp3+
7.56 ± 1.23 5.79 ± 1.05 2.97 ± 0.83 2.02 ± 0.83 3.59 ± 1.95 5.09 ± 1.95 4.61 ± 1.54 1.54 ± 1.02
CD4+ CD25+ 
Foxp3+
0.72 ± 0.34 1.22 ± 0.58 0.39 ± 0.37 0.88 ± 0.37 0.73 ± 0.49 0.22 ± 0.49 0.38 ± 0.32 0.08 ± 0.06
CD4+ CD25+ 
Foxp3-
16.43 ± 3.51 16.81 ± 3.97 13.15 ± 2.99 12.94 ± 2.99 20.41 ± 4.91 19.91 ± 4.91 5.58 ± 1.51 2.37 ± 1.51
CD4+ CD25- Foxp3- 3.54 ± 1.05 5.92 ± 1.57 0.94 ± 0.56 0.66 ± 0.56 2.92 ± 1.42 8.22 ± 1.42 0.49 ± 0.35 0.67 ± 0.42
Values are presented as mean ± standard deviation. HC: healthy controls; IFN-γ: interferon-gamma; IL: interleukin; UNOL: patients with untreated 
new-onset lupus.Arthritis Research & Therapy    Vol 11 No 5    Yang et al.
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'contaminated' with CD25low, it would bias function analysis of
CD4+CD25-Foxp3+ T cells from Teffs to Tregs [11].
Another possible explanation of the differences between the
study of Bonelli and colleagues [13] and ours is that there may
be a difference between untreated, newly diagnosed patients
and those more chronically ill who were drawn from an outpa-
tient population. It is possible that, as a consequence of ill-
ness, true CD25+ Tregs have become CD25-, whereas this
has not occurred yet in patients with new-onset disease.
Figure 3
Expressions of glucocorticoid-induced tumor necrosis factor receptor (GITR), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and chemok- ine receptor 4 (CCR4) on CD4+ subpopulations from patients with untreated new-onset lupus (UNOL) Expressions of glucocorticoid-induced tumor necrosis factor receptor (GITR), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and chemok-
ine receptor 4 (CCR4) on CD4+ subpopulations from patients with untreated new-onset lupus (UNOL). (A) CD4+ CD25- Foxp3+. (B) CD4+ CD25+ 
Foxp3+. (C) CD4+ CD25+ Foxp3-. (D) CD4+ CD25- Foxp3-.Available online http://arthritis-research.com/content/11/5/R153
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Figure 4
Expressions of interferon-gamma (IFN-γ), interleukin (IL)-4, IL-2, and IL-17 on CD4+ subpopulations from patients with untreated new-onset lupus  (UNOL) Expressions of interferon-gamma (IFN-γ), interleukin (IL)-4, IL-2, and IL-17 on CD4+ subpopulations from patients with untreated new-onset lupus 
(UNOL). (A) CD4+ CD25- Foxp3+. (B) CD4+ CD25+ Foxp3+. (C) CD4+ CD25+ Foxp3-. (D) CD4+ CD25- Foxp3-.Arthritis Research & Therapy    Vol 11 No 5    Yang et al.
Page 8 of 9
(page number not for citation purposes)
In our study, we found that the expressions of GITA, CTLA-4,
and CCR4 on CD4+CD25-Foxp3+  T cells resembled
CD4+CD25+Foxp3-  Teffs and were significantly less than
CD4+CD25+Foxp3+  Tregs. Moreover, unlike
CD4+CD25+Foxp3+ Tregs, CD4+CD25-Foxp3+ T cells also
synthesized IFN-γ, IL-4, IL-2, and IL-17, though less than
CD4+CD25+Foxp3-Teffs, suggesting that the abnormally
increased CD4+CD25-Foxp3+ T cells in UNOL patients were
not simple and pure Tregs.
Conclusions
CD4+CD25-Foxp3+ T cells in UNOL patients are different
from Tregs, both phenotypically and functionally. CD127 is not
an appropriate surface marker for intracellular Foxp3 in
CD4+CD25- T cells.
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